ArticleCureus2024
Efficacy and Safety of F-Biotic™ in Combination With Metformin for Type 2 Diabetes Mellitus: Results From a Randomized, Double-Blind Clinical Trial.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pharmacomicrobiomics in metabolic syndrome and type 2 diabetes: the microbiome-drug-host triad.Frontiers in pharmacology · 2026Review
- Probiotics,Metabolism open · 2025Article
- Prebiotic, probiotic, and postbiotic properties of fermented corn starch and their application in type 2 diabetes management.World journal of diabetes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study evaluated the effectiveness, safety, and tolerability of F-Biotic™ (Arishina Life Sciences, Karnataka, IND), a prebiotic containing 60% resistant starch derived from natural sources, in patients with Type 2 diabetes mellitus (T2DM) on stable metformin therapy.
methodsSeventy participants with T2DM, aged 25-70 years, were randomized into two groups: one receiving F-Biotic™ and the other a placebo, both administered daily for 12 weeks. Key outcomes included fasting blood sugar (FBS), postprandial blood sugar (PPBS), glycated hemoglobin (HbA1c), fasting insulin, insulin resistance (HOMA-IR), GLP-1 levels, lipid profile, and quality of life.
resultsThe F-Biotic™ group exhibited significant reductions in FBS from 150.18 ± 34.78 mg/dL at baseline to 134.24 ± 39.91 mg/dL by the end of the study, compared to an increase in the placebo group from 148.61 ± 42.13 mg/dL to 157.71 ± 47.84 mg/dL. PPBS decreased by -32.97 ± 67.18 mg/dL in the F-Biotic™ group versus an increase of 21.00 ± 36.59 mg/dL in the placebo group. GLP-1 levels increased significantly in the F-Biotic™ group, while they decreased in the placebo group. No significant changes were observed in HbA1c, fasting insulin, or HOMA-IR, and no adverse events related to the investigational product were reported.
conclusionF-Biotic™ appears to be a promising adjunctive therapy for T2DM, demonstrating significant improvements in glycemic control and quality of life without adverse events related to the investigational product. Further research with longer follow-ups and larger samples is needed to confirm these findings and evaluate long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.